PGX-YBG

PGX-YBG is a novel inhalable therapeutic composed of yeast beta-glucan microparticles processed using Pressurized Gas eXpanded (PGX) technology. This processing produces particles with higher surface area, lower density, and smaller, more uniform size distribution compared to conventional yeast beta-glucans. PGX-YBG acts as an immunomodulator by reprogramming pro-fibrotic M2-like macrophages into fibrosis-suppressing macrophages through activation of the Dectin-1 receptor without significant activation of TLR 2/4. It is being developed primarily for treatment and prevention of fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) and COVID-19 related lung fibrosis. The drug is designed for deep lung delivery via inhalation using a hand-held device, enabling it to reach alveolar tissues where fibrogenesis occurs. Preclinical studies in mice have shown safety and efficacy in preventing fibrogenesis and modulating immune response in lungs.

Other names

yeast beta glucanYBG